The NEO-1 gene may serve as a potential biomarker for predicting acute myocardial infarction
- 1Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin University, Changchun, China
- 2Department of Endocrinology, China-Japan Union Hospital of Jilin University, Jilin University, Changchun, China
Abstract
Objectives: This study elucidated the association between acute myocardial infarction (AMI) and Neogenin-1 (NEO-1) using proteomics to identify NEO-1 as a promising circulating biomarker for AMI risk prediction.
Methods: A total of 107 participants were included in the analysis, comprising 45 control subjects without coronary heart disease (non-coronary heart disease [NCHD]; as a control group) and 62 patients with AMI. Furthermore, mRNA levels were elucidated via RT-qPCR, whereas the protein content was measured using enzyme-linked immunosorbent assay (ELISA). Lastly, the acquired data were elucidated and compared.
Results: The data showed that relative to the NCHD group, the AMI group’s NEO-1 mRNA level in peripheral blood (PB) mononuclear cells was 1.47 times higher (p<0.05), whereas NEO-1 protein levels were 1.50 times higher (p<0.05). Furthermore, in AMI patients, the expression of NEO-1 was not related to smoking, total cholesterol, alcohol consumption, triglycerides, age, high-density lipoprotein cholesterol, hypertension, or platelets. Moreover, Logistic regression assessment revealed that AMI was associated with elevated NEO-1 expression and enhanced fasting blood glucose.
Conclusions: This study revealed that relative to the NCHD patients, AMI patients had elevated PB NEO-1 expression, which was an independent risk factor for AMI. These findings indicate that NEO-1 expression is a potential bio-index for AMI.
Related
- Evaluation of Clinical SYNTAX Score in Predicting New-Onset Atrial Fibrillation and Long-Term Prognosis in Patients Hospitalized with Non-ST Segment Elevation Myocardial Infarction
- Interpretable machine learning analysis of immune-inflammatory biomarkers for predicting no-reflow in patients with acute myocardial infarction after percutaneous coronary intervention.
- Advances and challenges in personalized cardiac modeling and simulation for predicting the risk of sudden death from malignant arrhythmias in post-myocardial infarction
- Case Report: A potential cardiovascular safety signal during batroxobin therapy for sudden sensorineural hearing loss: a three-case series of acute myocardial infarction
- Explainable Machine Learning for Predicting Major Adverse Renal and Cardiovascular Events in Acute Myocardial Infarction With Chronic Kidney Disease: Algorithm Development and Validation
BibTeX
@article{yang2026neo1,
title = {{The NEO-1 gene may serve as a potential biomarker for predicting acute myocardial infarction}},
author = {Zhaolin Yang and Heyu Meng and Jianjun Ruan and Zhiqi Yao and Fanbo Meng},
journal = {Open Medicine},
year = {2026},
month = oct,
doi = {10.1515/med-2026-1558},
url = {https://europepmc.org/article/PMC/PMC13718989},
note = {CC BY},
}
RIS
TY - JOUR
TI - The NEO-1 gene may serve as a potential biomarker for predicting acute myocardial infarction
AU - Zhaolin Yang
AU - Heyu Meng
AU - Jianjun Ruan
AU - Zhiqi Yao
AU - Fanbo Meng
PY - 2026
DA - 2026/10/30
JO - Open Medicine
DO - 10.1515/med-2026-1558
UR - https://europepmc.org/article/PMC/PMC13718989
AB - Objectives: This study elucidated the association between acute myocardial infarction (AMI) and Neogenin-1 (NEO-1) using proteomics to identify NEO-1 as a promising circulating biomarker for AMI risk prediction. Methods: A total of 107 participants were included in the analysis, comprising 45 control subjects without coronary heart disease (non-coronary heart disease [NCHD]; as a control group) and 62 patients with AMI. Furthermore, mRNA levels were elucidated via RT-qPCR, whereas the protein content was measured using enzyme-linked immunosorbent assay (ELISA). Lastly, the acquired data were elucidated and compared. Results: The data showed that relative to the NCHD group, the AMI group’s NEO-1 mRNA level in peripheral blood (PB) mononuclear cells was 1.47 times higher (p<0.05), whereas NEO-1 protein levels were 1.50 times higher (p<0.05). Furthermore, in AMI patients, the expression of NEO-1 was not related to smoking, total cholesterol, alcohol consumption, triglycerides, age, high-density lipoprotein cholesterol, hypertension, or platelets. Moreover, Logistic regression assessment revealed that AMI was associated with elevated NEO-1 expression and enhanced fasting blood glucose. Conclusions: This study revealed that relative to the NCHD patients, AMI patients had elevated PB NEO-1 expression, which was an independent risk factor for AMI. These findings indicate that NEO-1 expression is a potential bio-index for AMI.
SN - 1911-2092
SN - 2391-5463
ER -